Brief: Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations
10/05/2018 12:11
May 10 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* CIPHER PHARMACEUTICALS REPORTS Q1 2018 RESULTS
* Q1 LOSS PER SHARE $0.04 FROM CONTINUING OPERATIONS
* Q1 REVENUE $4.6 MILLION VERSUS $8.1 MILLION
* EXPECTS TO ADD SIX NEW PRODUCTS FROM ITS EXISTING PIPELINE
TO
ITS CANADIAN COMMERCIAL PORTFOLIO IN 2018 AND 2019
* CONTINUES TO PURSUE NEW IN-LICENSING OPPORTUNITIES AND
ACQUISITIONS TO FURTHER EXPAND ITS NEAR-TERM PRODUCT PIPELINE
* EXPECTS ITS GLOBAL LICENSING BUSINESS TO PROVIDE A "SOLID
BASE"
OF HIGH-MARGIN ROYALTY REVENUE IN 2018
Source text for Eikon: ID:nCNWbTjHDa
Further company coverage: CPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million